Table 1 Patient demographics and baseline characteristics

Female, n(%)

35 (54.69)

17 (51.52)

18 (58.06)

0.599

Age, y, Median[RG]

57(34–81)

54(39–81)

59(34–76)

0.220

< 65y, n(%)

40 (62.50)

23 (69.70)

17 (54.84)

≥ 65y, n(%)

24 (37.50)

10 (30.30)

14 (45.16)

Smoking, n(%)

0.510

Never

45 (70.31)

22 (66.67)

23 (74.19)

Former/Current

19 (29.69)

11 (33.33)

8 (25.81)

ECOG PS, n(%)

0.228

≤1, n(%)

45 (70.31)

21 (63.64)

24 (77.42)

≥2, n(%)

19 (29.69)

12 (36.36)

7 (22.58)

Adenocarcinoma, n(%)

60 (93.75)

31 (93.94)

29 (93.55)

1.000

RET fusion partner, n(%)

0.067

no-KIF5B

13 (24.53)

4 (14.29)

9 (36.00)

KIF5B

40 (75.47)

24 (85.71)

16 (64.00)

TP53, n(%)

14 (45.16)

7 (77.78)

7 (31.82)

0.044

Stage, n(%)

0.698

IIIC

3 (4.69)

1 (3.03)

2 (6.45)

IVA

23 (35.94)

11 (33.33)

12 (38.71)

IVB

38 (59.38)

21 (63.64)

17 (54.84)

Pleural effusion metastasis, n(%)

41 (64.06)

25 (75.76)

16 (51.61)

0.044

Hepatic metastases, n(%)

11 (17.19)

5 (15.15)

6 (19.35)

0.656

Bone metastasis, n(%)

30 (46.88)

13 (39.39)

17 (54.84)

0.216

CNS metastasis, n(%)

19 (29.69)

9 (27.27)

10 (32.26)

0.663

Basic lung disease, n(%)

27 (42.19)

14 (42.42)

13 (41.94)

0.968

Hypertension, n(%)

17 (26.56)

7 (21.21)

10 (32.26)

0.317

Diabetes, n(%)

9 (14.06)

7 (21.21)

2 (6.45)

0.181

Cerebrovascular disease, n(%)

7 (10.94)

3 (9.09)

4 (12.90)

0.930

Radiotherapy, n(%)

18 (28.12)

12 (36.36)

6 (19.35)

0.130

Thoracic radiotherapy, n(%)

10 (15.62)

8 (24.24)

2 (6.45)

0.106

Surgery, n(%)

13 (20.31)

5 (15.15)

8 (25.81)

0.290